PCVX
Vaxcyte, Inc.
$47.36
-2.87%
$7.0B
No data for this timeframe.
Vol
Market Cap$7.0B
Cap SizeMid Cap
Inst. Holders9 funds
Inst. Value$1.4B
Inst. Activity1 buys / 0 sells
Insider Activity0B / 7S
Insider Net $-$856.6K
SEC Reports5
Press Releases2
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001649094·Prev Close $48.76
Recent Activity
Jun 3, 2026
short_volume
Short Volume: PCVX — 59.8% short (0.3M / 0.5M)
Short: 305,550 | Exempt: 0 | TRF Vol: 510,828 | Short Ratio: 59.8% | Off-exchange volume (dark pool
Jun 2, 2026
Press
Vaxcyte dosed the first participant in a Phase 1 first-in-human study of VAX-A1, a prophylactic vaccine candidate for Gr
Impact 4/10
Jun 1, 2026
Insider
Wassil Jim sold 1,949 shares
CHIEF OPERATING OFFICER @ $49.40 ($96.3K)
May 6, 2026
SEC
Vaxcyte reported Q1 2026 net loss of $320.6M (-$2.30 per share), significantly worse than the consensus estimate of -$1.
8-K — Impact 7/10
May 1, 2026
Insider
Wassil Jim sold 2,250 shares
CHIEF OPERATING OFFICER @ $56.83 ($127.9K)
Apr 23, 2026
SEC
Vaxcyte, Inc. (PCVX) has filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting, scheduled for June 15
DEFA14A — Impact 3/10
Apr 8, 2026
SEC
Two Vaxcyte executives sold shares in the past week, including COO Jim Wassil selling $82K and SVP Elvia selling $180K a
CLUSTER — Impact 3/10
Apr 7, 2026
Insider
Cowan Elvia sold 3,000 shares
SVP, Finance & CAO @ $25.92 ($77.8K)
Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$109.00 (Feb 2026)
Current $47.36
Low $67.00
Median $110.00
High $163.00
9 analysts
$67.00
$163.00
Analyst Ratings
7Strong Buy
8Buy
2Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 26, 2026 | BTIG | MAINTAIN | Buy → Buy |
| Feb 2, 2026 | Guggenheim | REITERATE | Buy → Buy |
| Nov 10, 2025 | BTIG | REITERATE | Buy → Buy |
| Oct 16, 2025 | BTIG | MAINTAIN | Buy → Buy |
| Sep 12, 2025 | Goldman Sachs | INITIATE | Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current FY | $-8.48 ▼ -14.8% | $-9.81 — $-6.22 | -51% YoY | 7 |
| Next Q | $-2.16 ▼ -9.9% | $-2.66 — $-1.68 | -39% YoY | 7 |
| Next FY | $-7.42 ▼ -1.8% | $-11.47 — $-5.42 | 13% YoY | 7 |
| Current Q | $-2.10 ▼ -13.5% | $-2.55 — $-1.47 | -72% YoY | 7 |
Latest Reports
NEUTRAL
Press
4/10
Vaxcyte dosed the first participant in a Phase 1 first-in-human study of VAX-A1, a prophylactic vaccine candidate for Gr
Jun 2, 2026
BEARISH
8-K
7/10
Vaxcyte reported Q1 2026 net loss of $320.6M (-$2.30 per share), significantly worse than the consensus estimate of -$1.
May 6, 2026
NEUTRAL
DEFA14A
3/10
Vaxcyte, Inc. (PCVX) has filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting, scheduled for June 15
Apr 23, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $638.3M | — |
| VANGUARD GROUP INC | $562.6M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $59.7M | NEW |
| NORGES BANK | $56.7M | NEW |
| MORGAN STANLEY | $38.5M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 1, 2026 | Wassil Jim | SELL | $96.3K |
| May 1, 2026 | Wassil Jim | SELL | $127.9K |
| Apr 7, 2026 | Cowan Elvia | M | $77.8K |
| Apr 7, 2026 | Cowan Elvia | SELL | $180.0K |
| Apr 7, 2026 | Cowan Elvia | M | $0.00 |
9 institutional holders with $1.4B total value (30,398,886 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, CHARLES. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 13,834,514 | $638.3M | 45.5% | — |
| 2 | VANGUARD GROUP INC | 12,193,986 | $562.6M | 40.1% | — |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,293,830 | $59.7M | 4.3% | NEW |
| 4 | NORGES BANK | 1,228,939 | $56.7M | 4.0% | NEW |
| 5 | MORGAN STANLEY | 835,387 | $38.5M | 2.7% | ADD +38.7% |
| 6 | BANK OF AMERICA CORP /DE/ | 701,634 | $32.4M | 2.3% | TRIM -41.3% |
| 7 | WELLS FARGO & COMPANY/MN | 134,075 | $6.2M | 0.4% | ADD +47.7% |
| 8 | TWO SIGMA INVESTMENTS, LP | 111,310 | $5.1M | 0.4% | NEW |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 65,211 | $3.0M | 0.2% | TRIM -70.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 1,228,939 | — | $56.7M | 2025-Q4 |
| UBS Group AG | TRIM | 1,380,853 | 847,573 | -38.6% | $30.5M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 1,082,671 | 635,070 | -41.3% | $22.9M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 269,077 | 80,477 | -70.1% | $2.9M | 2025-Q3 |
| NORGES BANK | EXIT | 987,674 | 0 | -100.0% | $0.00 | 2025-Q3 |
| UBS Group AG | ADD | 1,080,396 | 1,380,853 | +27.8% | $44.9M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 790,812 | 1,082,671 | +36.9% | $35.2M | 2025-Q2 |
| NORGES BANK | NEW | — | 987,674 | — | $32.1M | 2025-Q2 |
| MORGAN STANLEY | ADD | 606,951 | 841,922 | +38.7% | $27.4M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 196,277 | 269,077 | +37.1% | $8.7M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 87,562 | — | $2.8M | 2025-Q2 |
| UBS Group AG | ADD | 736,561 | 1,080,396 | +46.7% | $40.8M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 54,077 | 196,277 | +263.0% | $7.4M | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | ADD | 72,275 | 106,735 | +47.7% | $4.0M | 2025-Q1 |
| NORGES BANK | EXIT | 1,100,286 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 111,573 | 736,561 | +560.2% | $60.3M | 2024-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 82,467 | 203,281 | +146.5% | $16.6M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 47,018 | 72,275 | +53.7% | $5.9M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 54,077 | — | $4.4M | 2024-Q4 |
| Duquesne Family Office LLC | DOUBLED | 42,965 | 86,265 | +100.8% | $7.1K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 1,295,837 | — | $148.1M | 2024-Q3 |
| MORGAN STANLEY | ADD | 409,692 | 694,869 | +69.6% | $79.4M | 2024-Q3 |
5 unique insiders with 7 transactions. Net insider value: -$856.6K ($0.00 bought, $856.6K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Wassil Jim | CHIEF OPERATING OFFICER | SELL | 1,949 | $49.40 | $96.3K |
| May 1, 2026 | Wassil Jim | CHIEF OPERATING OFFICER | SELL | 2,250 | $56.83 | $127.9K |
| Apr 7, 2026 | Cowan Elvia | SVP, Finance & CAO | M | 3,000 | $25.92 | $77.8K |
| Apr 7, 2026 | Cowan Elvia | SVP, Finance & CAO | SELL | 3,000 | $60.00 | $180.0K |
| Apr 7, 2026 | Cowan Elvia | SVP, Finance & CAO | M | 3,000 | $0.00 | $0.00 |
| Apr 1, 2026 | Wassil Jim | CHIEF OPERATING OFFICER | SELL | 1,412 | $58.14 | $82.1K |
| Mar 17, 2026 | Cowan Elvia | SVP, Finance & CAO | SELL | 1,487 | $55.39 | $82.4K |
| Mar 11, 2026 | Cowan Elvia | SVP, Finance & CAO | M | 2,500 | $25.92 | $64.8K |
| Mar 11, 2026 | Cowan Elvia | SVP, Finance & CAO | SELL | 2,500 | $58.59 | $146.5K |
| Mar 11, 2026 | Cowan Elvia | SVP, Finance & CAO | M | 2,500 | $0.00 | $0.00 |
| Mar 10, 2026 | Wassil Jim | CHIEF OPERATING OFFICER | SELL | 2,427 | $58.32 | $141.5K |
| Mar 9, 2026 | Wassil Jim | CHIEF OPERATING OFFICER | F | 975 | $59.32 | $57.8K |
| Mar 9, 2026 | Dhaliwal Harpreet S. | Chief Technical Ops Officer | F | 604 | $59.32 | $35.8K |
| Mar 9, 2026 | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | F | 3,685 | $59.32 | $218.6K |
| Mar 9, 2026 | GUGGENHIME ANDREW | PRESIDENT AND CFO | F | 1,021 | $59.32 | $60.6K |
| Mar 9, 2026 | Cowan Elvia | SVP, Finance & CAO | F | 495 | $59.32 | $29.4K |
| Mar 2, 2026 | GUGGENHIME ANDREW | PRESIDENT AND CFO | F | 1,009 | $61.98 | $62.5K |
| Mar 2, 2026 | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | F | 2,531 | $61.98 | $156.9K |
| Mar 2, 2026 | Cowan Elvia | SVP, Finance & CAO | F | 326 | $61.98 | $20.2K |
| Mar 2, 2026 | Dhaliwal Harpreet S. | Chief Technical Ops Officer | F | 465 | $61.98 | $28.8K |
| Mar 2, 2026 | Wassil Jim | CHIEF OPERATING OFFICER | F | 1,009 | $61.98 | $62.5K |
| Feb 28, 2026 | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | F | 2,863 | $61.98 | $177.4K |
| Feb 28, 2026 | GUGGENHIME ANDREW | PRESIDENT AND CFO | F | 898 | $61.98 | $55.7K |
| Feb 28, 2026 | Cowan Elvia | SVP, Finance & CAO | F | 243 | $61.98 | $15.1K |
| Feb 28, 2026 | Dhaliwal Harpreet S. | Chief Technical Ops Officer | F | 292 | $61.98 | $18.1K |
| Feb 28, 2026 | Wassil Jim | CHIEF OPERATING OFFICER | F | 898 | $61.98 | $55.7K |
| Feb 27, 2026 | Wassil Jim | CHIEF OPERATING OFFICER | A | 5,102 | $61.74 | $315.0K |
| Feb 26, 2026 | Cowan Elvia | SVP, Finance & CAO | A | 17,855 | $0.00 | $0.00 |
| Feb 26, 2026 | Dhaliwal Harpreet S. | Chief Technical Ops Officer | A | 53,409 | $0.00 | $0.00 |
| Feb 26, 2026 | Wassil Jim | CHIEF OPERATING OFFICER | A | 32,045 | $0.00 | $0.00 |
| Feb 26, 2026 | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | A | 105,110 | $0.00 | $0.00 |
| Feb 26, 2026 | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | A | 175,698 | $0.00 | $0.00 |
| Feb 26, 2026 | GUGGENHIME ANDREW | PRESIDENT AND CFO | A | 44,864 | $0.00 | $0.00 |
| Feb 26, 2026 | GUGGENHIME ANDREW | PRESIDENT AND CFO | A | 74,993 | $0.00 | $0.00 |
| Feb 26, 2026 | Cowan Elvia | SVP, Finance & CAO | M | 7,716 | $0.00 | $0.00 |
| Feb 26, 2026 | Cowan Elvia | SVP, Finance & CAO | A | 10,681 | $0.00 | $0.00 |
| Feb 26, 2026 | Dhaliwal Harpreet S. | Chief Technical Ops Officer | A | 46,424 | $0.00 | $0.00 |
| Feb 26, 2026 | Wassil Jim | CHIEF OPERATING OFFICER | A | 53,566 | $0.00 | $0.00 |
5 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 4 neutral. Avg impact: 4.4/10.
BEARISH
8-K
7/10
Vaxcyte reported Q1 2026 net loss of $320.6M (-$2.30 per share), significantly worse than the consen
May 6, 2026
NEUTRAL
DEFA14A
3/10
Vaxcyte, Inc. (PCVX) has filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting, s
Apr 23, 2026
NEUTRAL
CLUSTER
3/10
Two Vaxcyte executives sold shares in the past week, including COO Jim Wassil selling $82K and SVP E
Apr 8, 2026
NEUTRAL
8-K
4/10
Vaxcyte entered into an at-the-market (ATM) sales agreement with Leerink Partners LLC to sell up to
Feb 24, 2026
NEUTRAL
8-K
5/10
Vaxcyte reported its 2025 financial results, showing increased R&D and operating expenses leading to
Feb 24, 2026
Historical analyst distribution (last covering-analyst action Feb 2026): 88% buy across 17 analysts — 7 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$109.00 mean target (Feb 2026)
$67.00 Low
$163.00 High
| Metric | Value |
|---|---|
| Current Price | $47.36 |
| Target Low | $67.00 |
| Target Mean | $109.00 |
| Target Median | $110.00 |
| Target High | $163.00 |
| # Analysts | 9 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current FY 2026-12-31 |
$-8.48 | $-9.81 | $-6.22 | -50.7% | -14.8% | 0↑ 5↓ | $0.0B | 0.0% | 7 |
| Next Q 2026-09-30 |
$-2.16 | $-2.66 | $-1.68 | -38.7% | -9.9% | 0↑ 4↓ | $0.0B | 0.0% | 7 |
| Next FY 2027-12-31 |
$-7.42 | $-11.47 | $-5.42 | 12.5% | -1.8% | 1↑ 4↓ | $0.1B | 0.0% | 7 |
| Current Q 2026-06-30 |
$-2.10 | $-2.55 | $-1.47 | -71.9% | -13.5% | 0↑ 4↓ | $0.0B | 0.0% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-2.097 | |
| 7d ago | $-1.848 | -0.249 |
| 30d ago | $-1.848 | -0.249 |
| 60d ago | $-1.848 | -0.249 |
| 90d ago | $-1.595 | -0.502 |
11 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 8 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 26, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Feb 2, 2026 | Guggenheim | REITERATE | Buy | Buy |
| Nov 10, 2025 | BTIG | REITERATE | Buy | Buy |
| Oct 16, 2025 | BTIG | MAINTAIN | Buy | Buy |
| Sep 12, 2025 | Goldman Sachs | INITIATE | — | Neutral |
| Apr 22, 2025 | Cantor Fitzgerald | INITIATE | — | Overweight |
| Apr 8, 2025 | Needham | REITERATE | Buy | Buy |
| Apr 1, 2025 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Apr 1, 2025 | B of A Securities | MAINTAIN | Buy | Buy |
| Apr 1, 2025 | Needham | MAINTAIN | Buy | Buy |
| Mar 12, 2025 | Guggenheim | REITERATE | Buy | Buy |
| Feb 26, 2025 | Guggenheim | REITERATE | Buy | Buy |
| Feb 26, 2025 | Needham | REITERATE | Buy | Buy |
| Feb 24, 2025 | BTIG | REITERATE | Buy | Buy |
| Feb 11, 2025 | Needham | REITERATE | Buy | Buy |
| Dec 24, 2024 | BTIG | REITERATE | Buy | Buy |
| Dec 20, 2024 | Goldman Sachs | INITIATE | — | Buy |
| Nov 6, 2024 | Cantor Fitzgerald | REITERATE | — | Overweight |
| Nov 6, 2024 | Needham | REITERATE | Buy | Buy |
| Sep 10, 2024 | Mizuho | MAINTAIN | Outperform | Outperform |
| Sep 4, 2024 | B of A Securities | MAINTAIN | Buy | Buy |
| Sep 3, 2024 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Sep 3, 2024 | Jefferies | MAINTAIN | Buy | Buy |
| Sep 3, 2024 | Needham | MAINTAIN | Buy | Buy |
| Sep 3, 2024 | BTIG | MAINTAIN | Buy | Buy |
| Aug 7, 2024 | BTIG | REITERATE | Buy | Buy |
| Aug 7, 2024 | Needham | REITERATE | Buy | Buy |
| Jun 28, 2024 | Needham | REITERATE | Buy | Buy |
| Jun 20, 2024 | Cantor Fitzgerald | REITERATE | — | Overweight |
| May 9, 2024 | Cantor Fitzgerald | REITERATE | — | Overweight |
| May 9, 2024 | Needham | REITERATE | Buy | Buy |
| Apr 10, 2024 | Needham | REITERATE | Buy | Buy |
| Mar 12, 2024 | Mizuho | MAINTAIN | Buy | Buy |
| Feb 28, 2024 | Needham | MAINTAIN | Buy | Buy |
| Jan 2, 2024 | B of A Securities | MAINTAIN | Buy | Buy |
| Dec 7, 2023 | Mizuho | INITIATE | — | Buy |
| Nov 7, 2023 | Needham | REITERATE | Buy | Buy |
| Aug 22, 2023 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Aug 9, 2023 | Needham | REITERATE | Buy | Buy |
| May 9, 2023 | Needham | REITERATE | — | Buy |
| Apr 18, 2023 | TD Cowen | INITIATE | — | Outperform |
| Apr 18, 2023 | B of A Securities | MAINTAIN | — | Buy |
| Mar 1, 2023 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Feb 28, 2023 | Guggenheim | MAINTAIN | — | Buy |
| Feb 28, 2023 | Needham | REITERATE | — | Buy |
| Jan 3, 2023 | Needham | MAINTAIN | — | Buy |
| Dec 16, 2022 | SVB Leerink | INITIATE | — | Outperform |
| Dec 15, 2022 | Guggenheim | INITIATE | — | Buy |
| Nov 17, 2022 | BTIG | INITIATE | — | Buy |
| Nov 8, 2022 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 8 | 2 | 0 | 0 | 88% | |
| May 1, 2026 | 7 | 8 | 2 | 0 | 0 | 88% | |
| Apr 1, 2026 | 7 | 8 | 2 | 0 | 0 | 88% | |
| Mar 1, 2026 | 7 | 8 | 2 | 0 | 0 | 88% | |
| Feb 1, 2026 | 7 | 8 | 2 | 0 | 0 | 88% | |
| Jan 1, 2026 | 7 | 7 | 2 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 3, 2026
short_volume
Short Volume: PCVX — 59.8% short (0.3M / 0.5M)
Short: 305,550 | Exempt: 0 | TRF Vol: 510,828 | Short Ratio: 59.8% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
fda
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
<p align="center"><strong><em>First-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection
Jun 2, 2026
short_volume
Short Volume: PCVX — 72.4% short (0.4M / 0.6M)
Short: 409,547 | Exempt: 2,094 | TRF Vol: 565,655 | Short Ratio: 72.4% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: PCVX — 79.2% short (0.6M / 0.8M)
Short: 612,554 | Exempt: 0 | TRF Vol: 773,680 | Short Ratio: 79.2% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: PCVX — 76.8% short (0.5M / 0.6M)
Short: 488,708 | Exempt: 0 | TRF Vol: 636,617 | Short Ratio: 76.8% | Off-exchange volume (dark pool + OTC)
May 27, 2026
short_volume
Short Volume: PCVX — 67.7% short (0.4M / 0.6M)
Short: 373,199 | Exempt: 392 | TRF Vol: 551,407 | Short Ratio: 67.7% | Off-exchange volume (dark pool + OTC)
May 26, 2026
short_volume
Short Volume: PCVX — 65.3% short (0.4M / 0.7M)
Short: 443,779 | Exempt: 0 | TRF Vol: 679,418 | Short Ratio: 65.3% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: PCVX — 62.3% short (0.4M / 0.7M)
Short: 446,463 | Exempt: 17 | TRF Vol: 716,927 | Short Ratio: 62.3% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: PCVX — 68.1% short (0.4M / 0.6M)
Short: 392,713 | Exempt: 0 | TRF Vol: 577,054 | Short Ratio: 68.1% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: PCVX — 68.7% short (0.5M / 0.7M)
Short: 452,832 | Exempt: 2,619 | TRF Vol: 659,480 | Short Ratio: 68.7% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_volume
Short Volume: PCVX — 70.4% short (0.5M / 0.7M)
Short: 517,865 | Exempt: 0 | TRF Vol: 735,430 | Short Ratio: 70.4% | Off-exchange volume (dark pool + OTC)
May 11, 2026
earnings_calendar
PCVX Q1 2026 Earnings Scheduled — 2026-05-11
May 6, 2026
earnings
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
<p align="center"><strong><em>Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive P
May 6, 2026
short_volume
Short Volume: PCVX — 60.2% short (0.4M / 0.7M)
Short: 421,160 | Exempt: 90 | TRF Vol: 699,443 | Short Ratio: 60.2% | Off-exchange volume (dark pool + OTC)
May 5, 2026
earnings_calendar
PCVX Q1 2026 Earnings Scheduled — 2026-05-05